Abstract:This formulated PDMN constitutes a biological product that preferentially colonizes and penetrates into tumor regions, as well as activates STING on dendritic cells, leading to the differentiation of cell‐mediated immunity and secretion of proinflammatory cytokines. This STING‐amplified biotherapy efficiently restrains the growth of local and distant tumors, and shows synergy when combined with PD‐1 blockade to elicit a long‐lived immunity. Stimulator of interferon genes (STING) connects the innate immunity to potent adaptive immunity via multiple pathways, which play a critical role in cancer treatment. Clinical application of STING agonists is mainly restrained due to the metabolic instability caused by intrinsic cyclic dinucleotide ligands. Previously, an orally available non‐nucleotide human STING agonist, MSA‐2 is presented, and to further improve its therapeutic efficacy, this work leverages the nonpathogenic Escherichia coli Nissle 1917 for tumor‐targeted delivery of the STING agonist by coating biocompatible polydopamine on the bacterial surface, termed as PDMN. The engineered bacterial delivery platform holds potential in elevating levels of type I interferon (IFN) along with proinflammatory cytokines and inducing maturation on dendritic cells. Intravenous administration of PDMN with laser irradiation to the tumor region promotes IFN‐β expression in a tumor microenvironment and mounts both the innate and adaptive immune responses, leading to profound regressions of established melanoma and hepatocellular carcinoma in mice. By synergized with anti‐PD‐1 therapy, a substantial long‐lived protective immunity is generated, capable of preventing distant tumor metastases. Hence, this study identifies a STING‐amplified biotherapy to shape the cell‐mediated antitumor immunity, serving as a potential personalized cancer vaccine with enhanced biosafety and immune activation profile for diverse applications.

Targeting STING with Cyclic Di-Gmp Greatly Augmented Immune Responses of Glycopeptide Cancer Vaccines

Tumor-responsive Covalent Organic Polymeric Nanoparticles Enhancing STING Activation for Cancer Immunotherapy

Cell-to-cell communications of cGAS-STING pathway in tumor immune microenvironment.

STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice

Self-Assembled STING-Activating Coordination Nanoparticles for Cancer Immunotherapy and Vaccine Applications

Engineering cGAS-agonistic oligonucleotides as therapeutics for cancer immunotherapy

pH‐Responsive STING‐Activating DNA Nanovaccines for Cancer Immunotherapy

Engineered Nanovaccine Targeting Clec9a + Dendritic Cells Remarkably Enhances the Cancer Immunotherapy Effects of STING Agonist

Pam3CSK4-CDGSF Augments Antitumor Immunotherapy by Synergistically Activating TLR1/2 and STING

Assembly of 2′,3′-Cyclic Guanosine Monophosphate-Adenosine Monophosphate and Their Spontaneous Intracellular Disassembly for Enhanced Antitumor Immunity Via Natural STING Pathway Activation

Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine

Cyclic Diguanylate Analogues: Facile Synthesis, STING Binding Mode and Anti-Tumor Immunity Delivered by Cytidinyl/cationic Lipid

Supramolecular Cyclic Dinucleotide Nanoparticles for STING-Mediated Cancer Immunotherapy

piSTING: A Pocket‐Independent Agonist Based on Multivalency‐Driven STING Oligomerization

CASTING:A Potent Supramolecular Strategy to Cytosolically Deliver STING Agonist for Cancer Immunotherapy and SARS-CoV-2 Vaccination

Dual-pathway STING activation and chemodynamic therapy for improved anti-tumor therapy

Engineering the Immune Adaptor Protein STING as a Biologic

Potentiating the Systemic Immunity by Bacteria‐Delivered Sting Activation in a Tumor Microenvironment

cGAS-STING pathway in cancer biotherapy

Co-delivery of doxorubicin and STING agonist cGAMP for enhanced antitumor immunity

Engineering the Immune Adaptor Protein STING as a Functional Carrier